Healthcare

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell…

3 months ago

Bausch Health Announces Results of Special Meeting of Shareholders

LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the…

3 months ago

Bausch Health Announces Results of Special Meeting of Shareholders

LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the…

3 months ago

Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October “Fourth Friday at Four” Webinar

Live session on October 24th will showcase how the VETGuardian Monitor enhances patient care, improves workflow efficiency, and expands global…

3 months ago

Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October “Fourth Friday at Four” Webinar

Live session on October 24th will showcase how the VETGuardian Monitor enhances patient care, improves workflow efficiency, and expands global…

3 months ago

NEXGEL to Present at the LD Micro Main Event XIX Conference on October 19-21

LANGHORNE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of…

3 months ago

Series A Round Valuation: ¥9 Billion: MEDIROM MOTHER Labs Inc. Decides to Make an Investment from Internal Investors

TOKYO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter…

3 months ago

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trialTrial will…

3 months ago

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™…

3 months ago

Humber River Health Achieves Excellent Scores, Remarkably Low Rate of Patient Harm, Leading Provincial and National Benchmarks

Humber River Hospital Humber River Health’s hospital harm rates in comparison to the provincial and national averages. Data provided by…

3 months ago